After multiple testing correction, seven out of the 9 chemokines identified in the full dataset (CCL2, CCL11, CCL13, CCL17, CCL22, CCL26 and CXCL10) were also significantly reduced in FXS male patients as compared to male controls (adjusted p-value < 0.05, Additional file 3: Table S2). The gene discussed is CCL2; the disease is fragile X syndrome.